500 pages in. 2 pages out.
Unified Network for Molecular Insights & Reporting Intelligence
UNMIRI turns NGS genomic reports into a 2-page Actionable Insight — top 3 treatment recommendations, contraindications, and matching clinical trials. Clinical output is rendered by deterministic templates; every claim cited. Built for the oncologist's 15-minute consult.
HIPAA-ready · BAA-backed · Zero-retention LLM pipeline · US data residency
Actionable Insight
NSCLC Adenocarcinoma — Synthetic Patient
Osimertinib (Tagrisso)
EGFR L858R — FDA-approved first-line
Erlotinib + Ramucirumab
EGFR exon 19/21 — OncoKB Level 2A
Carboplatin + Pemetrexed
Co-mutation TP53 — consider platinum doublet
Contraindication flagged
PD-L1 <1% — checkpoint inhibitor monotherapy not indicated. Avoid pembrolizumab first-line.
Report stats
487
source pages ingested
2
pages delivered
1.4s
processing time
Clinical trial match
NCT05116866
MARIPOSA-2 · Phase III · EGFR-mutant NSCLC
3M+
solid tumor NGS tests ordered annually in the US
487
average pages in a raw genomic report
2–4 hrs
a bioinformatician spends per complex NGS summary
Built for diagnostic labs like yours
“AI outperforms human oncologists at NGS report summarization — on accuracy, completeness, and clinical relevance.”
The study compared structured AI summaries against manual physician interpretation of 200 solid-tumor NGS reports. The gap wasn't marginal. The bottleneck isn't the sequencer — it's the interpretation layer that sits between the data and the clinician.
Source: Northwestern Feinberg School of Medicine, April 2026
500 pages, no prioritization
Raw NGS outputs are dense by design — they're built for bioinformaticians, not oncologists making treatment calls in a 15-minute consult.
2–4 hours per complex case
Your bioinformatician is spending half a working day writing a manual summary that a competing lab is automating in seconds.
Revenue walks to Tempus
When oncologists can't get interpreted reports fast, complex cases go to Tempus or Foundation Medicine — and the billing follows. Your sequencing work funds your competitor.
The hard truth: “We sequence the tumor and hand it off — and Tempus gets the credit for the interpretation.”
— Common sentiment from regional lab directors
How it works
Three steps. Seconds to insight.
UNMIRI sits between your sequencer and the oncologist — translating genomic data into clinical action without touching your EHR.
Ingest
Raw NGS report arrives
Your LIMS sends the 500-page genomic report to UNMIRI via REST API. AWS Textract plus per-lab parsers convert it into structured variant JSON. No EHR integration required.
VCF · FHIR R4 · PDF · HL7
Analyze
Graph-based retrieval matches every variant
UNMIRI's knowledge graph — built on OncoKB, ClinVar, ClinicalTrials.gov, and openFDA drug labels — traverses variant → drug → evidence level → contraindication via deterministic Cypher queries. Same input, same output, every time.
OncoKB · ClinVar · ClinicalTrials.gov · openFDA
Deliver
Deterministic templates render the cheat sheet
The 2-page Actionable Insight is rendered by typed templates from structured graph output, not generated by an LLM. Every claim is cited. Templates can't hallucinate.
PDF · JSON · EHR-ready
The knowledge graph drives clinical reasoning. Deterministic templates render the output. LLMs are used narrowly — for extraction edge cases and long-tail variant fallback — and never in the clinical path itself.
Before & after
This is what your oncologists deal with today.
One delivers raw data. The other delivers a decision.
Oncologist still reading on page 12 of 487. Consult in 8 minutes.
Top 3 Recommendations — Evidence-graded
Osimertinib (Tagrisso)
EGFR L858R · Level 1 · FDA-approved first-line
Erlotinib + Ramucirumab
EGFR exon 21 · OncoKB Level 2A · FDA-approved
Carboplatin + Pemetrexed
TP53 co-mutation · Level 2B · consider platinum doublet
Contraindication flagged
PD-L1 <1% — immunotherapy monotherapy not indicated. Avoid pembrolizumab first-line.
Matching clinical trial
NCT05116866 — MARIPOSA-2
Phase III · EGFR-mutant NSCLC · Enrolling
Ready for the 15-minute consult. Synthetic data — demonstration only.
Who it's for
Built for the people who run regional diagnostic labs.
We're not selling to oncologists. We're selling to the labs that serve them — and we know exactly who reads the procurement docs.
Move up the value chain.
You're running one of the best NGS labs in the region. Your oncologist clients are getting 500-page PDFs. Tempus is calling them with interpreted reports. UNMIRI lets you offer what Tempus offers — without ceding your client relationships to do it.
An architecture you can defend.
The knowledge graph reasons over variants. Deterministic templates render the output. LLMs are used narrowly for extraction edge cases and long-tail fallback — never on the clinical path. REST API with full audit logging, US-only data residency, and a data-flow diagram you can put in front of your CAP inspector.
The math is straightforward.
$100 per report. A mid-size lab running 200 NGS panels/month spends $20K/month with UNMIRI — versus one bioinformatician at $120K/year or a single lost oncology client worth $500K–$2M in annual volume.
Not a fit: academic medical centers with 10+ bioinformaticians, national labs (Tempus/Foundation-scale), or labs running fewer than 50 NGS panels/month.
Compliance & security
We can answer your security questionnaire today.
Most AI vendors go vague when procurement asks about PHI. We've built our compliance posture into the architecture — not bolted it on afterward.
Ready to offer interpreted NGS reports?
Pre-pilot. Onboarding 2–3 regional labs for retrospective pilots in the mid-Atlantic. We run a structured 30-day engagement: your NGS data, your LIMS workflow, your oncologist clients. You see the output before you commit. BAA and data-flow diagram ready for your legal team on day one.
No EHR integration required · LIMS REST API · BAA on request · US-only data residency